A study published in the Journal of Urology in 2023 indicated that prostate cancer patients with low testosterone levels may face a higher risk of cancer progression to a more aggressive form while under active surveillance (Abufaraj et al., 2023). This finding directly challenges the long-held, but increasingly outdated, belief that testosterone replacement therapy (TRT) inherently poses a significant prostate cancer risk. Contemporary evidence continues to dismantle this myth, advocating for a nuanced understanding of testosterone’s role in prostate health.

Last Updated: October 2024

The Historical Misconception: Reexamining the “Testosterone-Prostate Cancer Link”

For decades, the medical community operated under the assumption that testosterone “fueled” prostate cancer growth. This fear originated from a seminal 1941 paper by Huggins and Hodges, which demonstrated that castrating men with metastatic prostate cancer or administering estrogen significantly reduced tumor size and improved symptoms, while administering testosterone increased growth in advanced cases. This foundational work, while revolutionary at the time, led to a blanket contraindication for TRT in men with prostate cancer, and even a cautious approach in healthy men.

This perspective, however, failed to differentiate between supraphysiological (pharmacological) testosterone levels and physiological restoration. It also overlooked the critical concept of prostate androgen receptor saturation. As Dr. Abraham Morgentaler and Dr. Abdulmaged M. Traish pointed out in their 2009 paper, “Testosterone and prostate cancer: an historical perspective on a 60-year-old myth” in the Journal of Sexual Medicine, the prostate’s androgen receptors become fully saturated at relatively low testosterone concentrations. This means that increasing testosterone levels within the physiological range (e.g., from 150 ng/dL to 800 ng/dL) does not lead to further prostate growth stimulation once those receptors are saturated. It’s not a linear “more T equals more cancer” relationship, but rather a threshold effect.

The Saturation Model

The “saturation model” proposes that androgen receptors in prostate cells are maximally stimulated at normal physiological testosterone levels. Once these receptors are saturated, increasing testosterone further, within the normal or even slightly above normal range, does not lead to additional growth or proliferation of prostate cells. This explains why men with high-normal testosterone levels are not at a higher risk of prostate cancer than men with low-normal levels. The prostate simply cannot respond to indefinitely increasing levels of the hormone.

Current Clinical Evidence: Dispelling the Fear

Modern research, spanning thousands of men over decades, consistently demonstrates that TRT in hypogonadal men does not increase the risk of developing prostate cancer. Furthermore, the landscape has significantly shifted regarding TRT in men with a history of prostate cancer.

TRT and Prostate Cancer Incidence

Numerous observational studies and meta-analyses have found no increased incidence of prostate cancer in men receiving TRT. A comprehensive review by Pastuszak et al. in The Urologic Clinics of North America (2014) highlighted that contemporary evidence does not support an association between TRT and increased prostate cancer risk or progression. Instead, maintaining healthy testosterone levels, typically achieved with dosages such as 100–200mg testosterone cypionate or enanthate per week, targeting total testosterone levels between 500–800 ng/dL and free testosterone between 15–25 pg/mL, is now understood to be beneficial for overall male health without significantly impacting prostate cancer risk.

TRT After Prostate Cancer Treatment

Perhaps the most significant paradigm shift is the growing body of evidence supporting TRT in select men after successful prostate cancer treatment. This includes men who have undergone radical prostatectomy or radiation therapy. Studies have shown that carefully selected patients, typically those with low-risk cancer treated effectively, can safely receive TRT without an increased risk of biochemical recurrence (PSA rising after treatment, indicating potential cancer return).

For example, a study by Khera et al. (2009) published in Cancer followed men who underwent radical prostatectomy for prostate cancer and subsequently received TRT for symptomatic hypogonadism. The study found no increase in prostate cancer recurrence rates in these men compared to untreated controls, with a median follow-up of 2.5 years. Longer-term data continues to support these findings, demonstrating the safety and quality of life benefits of restoring testosterone in prostate cancer survivors.

The Role of Low Testosterone in Prostate Cancer Progression

Counterintuitively, some research suggests that low testosterone may be associated with more aggressive prostate cancer. The study by Abufaraj et al. (2023) mentioned earlier underscores this. Another line of research suggests that low testosterone can be a marker for more aggressive disease in men undergoing active surveillance for localized prostate cancer. This challenging perspective suggests that maintaining healthy, physiological testosterone levels might actually be protective or, at the very least, not harmful, in certain prostate cancer contexts.

Evolving Clinical Guidelines and Anti-Gatekeeping

The collective body of modern research has begun to influence clinical guidelines and regulatory bodies. The long-standing, often arbitrary, contraindications for TRT based solely on a history of prostate cancer are being reconsidered.

Regarding the FDA’s stance, a statement from Urology Times in December 2025 noted that experts are urging the FDA to revisit its labeling for TRT, specifically stating that “the current warning labels and contraindications for those with prostate cancer or suspected prostate cancer are not supported by contemporary evidence and should be removed.” This signifies a monumental shift away from outdated gatekeeping practices rooted in incomplete historical data.

The Endocrine Society’s guidelines, while still among the most cautious, have also evolved. While advising against TRT in patients with an unevaluated prostate nodule, PSA >4ng/mL, or PSA >3ng/mL in high-risk patients (e.g., African Americans), these are largely diagnostic rather than absolute contraindications for life. Critically, these guidelines are continually under review as new data emerges.

The historical 264 ng/dL lower bound for total testosterone, often used by physicians to deny TRT access, is a prime example of arbitrary gatekeeping. This threshold was largely calibrated from studies in the 1970s that included populations of sick and elderly men, who naturally have lower testosterone levels. It does not reflect optimal health or symptom resolution for many men. A more accurate understanding recognizes that many men experience symptoms of hypogonadism well above this arbitrary cutoff, benefiting significantly from TRT that brings their total testosterone into a healthy range (e.g., 500-800 ng/dL).

Monitoring Prostate Health on TRT

Even with the debunking of historical myths, responsible TRT management includes routine prostate health monitoring. This typically involves:

PSA (Prostate-Specific Antigen) Testing: A baseline PSA test is recommended before initiating TRT. Subsequent PSA tests are typically performed at 3, 6, or 12 months after initiation, and then annually. A rapid rise in PSA (e.g

TRT and Prostate Cancer: Challenging Old Beliefs with New Research